{"entity":{"id":"nct03393884","kind":"trial","name":"Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)","aka":["OVATION 2"],"tldr":"A phase 1/2 trial of Carboplatin, Paclitaxel / nab-paclitaxel in ovarian cancer, run by Imunon, active and no longer recruiting.","summary":"Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) is a phase 1/2 interventional study registered as NCT03393884 by Imunon, with 130 participants planned, started 2018-09-05 and due to reach its primary completion in 2024-07-25. Interventions recorded: IMNN-001, Carboplatin, Paclitaxel. Conditions listed: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03393884","url":"https://clinicaltrials.gov/study/NCT03393884"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["carboplatin","paclitaxel"],"companies":["imunon"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03393884","phase":"1/2","setting":"A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer","sponsor":"Imunon","participation":[{"nct":"NCT03393884","source":"https://clinicaltrials.gov/study/NCT03393884","fetchedAt":"2026-10-07T16:53:01.545Z","studySha256":"187f2f359bfdc1108d052396c20c8df3748dbbd847d09aeaad5597990354e803","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-05-04","leadSponsor":"Imunon","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":130,"enrolmentType":"ESTIMATED","siteCount":21,"recruitingSiteCount":0,"countries":["Canada","United States"]}],"started":"2018-09-05","startedType":"actual","enrolled":130,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03393884/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/"}]}}